Ashling Wahner

Adjuvant Durvalumab Plus Tremelimumab Yields DFS Advantage in Resected RCC

November 6th 2025

Treatment with adjuvant durvalumab plus tremelimumab resulted in a DFS benefit vs active monitoring in RCC, particularly in the higher-risk population.

UGN-103 Yields High 3-Month CR Rate in Low-Grade, Intermediate-Risk NMIBC

November 6th 2025

UGN-103 produced a 77.8% 3-month CR rate in patients with low-grade, intermediate-risk NMIBC.

Dr Visco on Unmet Needs for Patients With Mantle Cell Lymphoma

November 6th 2025

Carlo Visco, MD, explains the need to study treatment outcomes and develop novel therapies for patients with mantle cell lymphoma harboring TP53 mutations.

Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

November 5th 2025

Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.

Dr Mayer on PRO Data With Camizestrant Plus CDK4/6 Inhibition in ESR1+ Breast Cancer

November 5th 2025

Erica L. Mayer, MD, MPH, discussed PRO data in ESR1 mutation–emergent breast cancer following switch therapy to camizestrant plus a CDK4/6 inhibitor.

Dr Tarantino on the Efficacy of Neoadjuvant T-DXd/THP in High-Risk HER2+ Breast Cancer

November 5th 2025

Paolo Tarantino, MD, PhD, discussed the clinical implications of the DESTINY-Breast11 trial of T-DXd/THP in high-risk, HER2-positive early breast cancer.

Dr Tolaney on the Efficacy of T-DXd in HER2+ Breast Cancer in the Post-Neoadjuvant Setting

November 5th 2025

Sara M. Tolaney, MD, MPH, discussed the use of T-DXd in patients with HER2-positive breast cancer with residual disease after neoadjuvant therapy.

Dr Dent on the Potential Role of Dato-DXd for Immunotherapy-Ineligible TNBC

November 5th 2025

Rebecca Dent, MD, MSc, FRCP, discussed the future implications of data with first-line Dato-DXd in locally recurrent inoperable or metastatic TNBC.

Dr Kalinsky on the Importance of Novel Second-Line Therapies for HR+ Breast Cancer

November 5th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses research needs to improve treatment strategies in the post-CDK4/6 inhibitor setting for HR-positive breast cancer.

Dr Haake on the Rationale for a Tumor Subtype Analysis of Cabozantinib Plus Nivolumab in Metastatic ccRCC

November 5th 2025

CSF1R Blockade With AMB-05X May Improve Tumor Control in ctDNA+ CRC

November 5th 2025

A phase 2 study is using ctDNA positivity to select patients with CRC who may benefit from treatment with the CSF1R-directed antibody AMB-05X.

GEP-NET–Focused Research Refines Optimal PRRT Use in Well-Differentiated Disease

November 5th 2025

Rohit Thummalapalli, MD, discusses the treatment paradigm for patients with GEP-NETs and the role of Lutetium Lu 177 dotatate across lines of therapy.

Bladder Cancer Symptom Awareness and Testing Are Crucial for Early Detection in Women: With Martha K. Terris, MD, FACS

November 4th 2025

Martha K. Terris, MD, FACS, discusses unique considerations for bladder cancer diagnosis and treatment among women

Positive KEYNOTE-B96 Data Show Role for Immunotherapy–Based Regimens in PROC

November 4th 2025

Nicoletta Colombo, MD, PhD, discusses clinical implications for integrating immunotherapy into the treatment arsenal for platinum-resistant ovarian cancer.

ADC and CDK4/6 Inhibitor Research Set to Refine TNBC and ER+ Breast Cancer Treatment Strategies

November 4th 2025

Yuan Yuan, MD, PhD, discusses the use of sacituzumab govitecan in TNBC and remaining questions about the use of CDK4/6 inhibitors in ER-positive disease.

Dr Lee on the Importance of Multidisciplinary Collaboration in NSCLC Management

November 4th 2025

Percy Lee, MD, discusses the critical nature of multidisciplinary collaboration and notes lingering questions about the optimal use of SABR in NSCLC.

Oncology Experts Dive Into Top Data From ESMO 2025

November 4th 2025

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Meta Analysis Highlights Benefits of JAK Inhibitors vs BAT in Myelofibrosis

November 3rd 2025

Findings from a meta analysis showed that JAK inhibitors were associated with improved outcomes vs best available therapy in myelofibrosis.

177Lu-Edotreotide Demonstrates Efficacy and Notable Safety Advantage in Advanced GEP-NETs

November 3rd 2025

Jaume Capdevila, MD, PhD, discusses the potential for 177Lu-edotreotide for the treatment of patients with neuroendocrine tumors.

Vorasidenib Sustains Long-Term Benefit in IDH-Mutant Grade 2 Glioma

November 3rd 2025

Long-term follow-up results show vorasidenib prolongs PFS and reduces tumor progression vs placebo in IDH-mutant grade 2 glioma.